
The company announced post market hours Thursday that it had settled a patent suit in the US for sale of a generic version cancer drug in that market. The short-term range for the stock is 4,546-5,054.
from Markets-Economic Times https://ift.tt/3cbd8x0
via
IFTTT
No comments